Phase II Study of RO4929097 to Eradicate Residual Disease in Patients With Multiple Myeloma Post Single Autologous Stem Cell Transplant.

Trial Profile

Phase II Study of RO4929097 to Eradicate Residual Disease in Patients With Multiple Myeloma Post Single Autologous Stem Cell Transplant.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 04 Mar 2017

At a glance

  • Drugs RG 4733 (Primary)
  • Indications Multiple myeloma
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 19 Jul 2016 Status changed from withdrawn prior to enrolment to discontinued.
    • 24 Jan 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 03 Jan 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top